Federated Hermes’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Federated Hermes’s Portfolio HARP Stock Details HARP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-113	Closed	-$804	–	2254
2023 Q2	$804	Sell	113 -172	-60%	-$1.19K	﹤0.01%	2035
2023 Q1	$2.12K	Buy	285 +18	+7%	+$151	﹤0.01%	2000
2022 Q4	$1.94K	Buy	267 +34	+15%	+$286	﹤0.01%	2006
2022 Q3	$2K	Sell	233 -13,046	-98%	-$244K	﹤0.01%	1997
2022 Q2	$254K	Buy	13,279 +4,121	+45%	+$107K	﹤0.01%	1501
2022 Q1	$455K	Sell	9,158 -3,622	-28%	-$188K	﹤0.01%	1477
2021 Q4	$965K	Sell	12,780 -22	-0.2%	-$1.5K	﹤0.01%	1286
2021 Q3	$1.01M	Sell	12,802 -23	-0.2%	-$2.31K	﹤0.01%	1275
2021 Q2	$1.78M	Buy	12,825 +12,808	+75,341%	+$2.44M	﹤0.01%	1132
2021 Q1	$4K	Buy	+17	New	+$3.41K	﹤0.01%	2086

Other funds holding HARP

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Federated Hermes's HARP Position: Q3 2023 in Review

Federated Hermes sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q3 2023, closing a stake of 113 shares — an estimated $804 sold.

Federated Hermes first reported a position in HARP in Q1 2021 and held it in 10 quarters. The position peaked at $1.78M in Q2 2021. 32 funds tracked by Wall St. Rank hold HARP as of Q3 2023.

Federated Hermes reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Federated Hermes sold 113 Harpoon Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $804.
Federated Hermes first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Federated Hermes's Harpoon Therapeutics, Inc. Common Stock position peaked at $1.78M in Q2 2021.
32 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Federated Hermes's 13F filing for Q3 2023, filed 13 Nov 2023.